Cerlapirdine Explained

Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia.^[1] In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events,^[2] but no further development has occurred since 2011.^[3]

It exerts its effects by acting as a selective 5-HT₆ receptor antagonist.^[1]

See also

• Idalopirdine
• Latrepirdine

Notes and References

1. Codony X, Vela JM, Ramírez MJ . 5-HT(6) receptor and cognition . . 11 . 1 . 94–100 . February 2011 . 21330210 . 10.1016/j.coph.2011.01.004 . 10171/18451 . free .
2. Book: Franco Borsini . International review of neurobiology: Pharmacology of 5-HT6 receptors. Part 2 . 25 October 2011 . 2011 . Academic Press . 978-0-12-385902-0 . 5.
3. http://adisinsight.springer.com/drugs/800025908 Drug Profile: Cerlapirdine